Michael Waggoner, DO
Cornea and External Diseases Specialist · Rogers, ARNPI 1295963999
Payments from drug & device makers
Across 144 payments — averaging $197.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$15K
- Glaukos Corporation$6K
- Carl Zeiss Meditec, Inc.$2K
- Ocular Therapeutix, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$501
- Biotissue Holdings Inc.$427
- plus $2K from 16 others
What the payments were for
- Consulting fees$16,87569%
- Speaking & faculty fees$260%
- Food & beverage$4,98320%
- Entertainment$620%
- Other$2,44310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 13 | $14,833 |
| Glaukos Corporation | 22 | $5,597 |
| Carl Zeiss Meditec, Inc. | 3 | $2,475 |
| Ocular Therapeutix, Inc. | 20 | $2,349 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $501 |
| Biotissue Holdings Inc. | 7 | $427 |
| AbbVie | 21 | $426 |
| Alcon | 10 | $388 |
| Carl Zeiss Meditec USA, Inc. | 1 | $293 |
| Johnson & Johnson Surgical Vision, Inc. | 17 | $286 |
| Bausch & Lomb Americas Inc. | 7 | $244 |
| Ivantis, Inc | 1 | $119 |
| Rayner Intraocular Lenses Limited | 1 | $95 |
| Optos, Inc. | 1 | $62 |
| Amgen(2 entities) | 3 | $60 |
| Tarsus Pharmaceuticals, Inc. | 3 | $58 |
| Novartis | 3 | $42 |
| Beaver-visitec International, Inc. | 1 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| The Cameron-ehlen Group, Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$14,520
- DEXTENZA$2,150
- VERACITY SURGICAL$1,925
- KXL System$557
- Photrexa$557
- TORIC$371
- iStent inject W$307
- IOLMaster 700$293
- Photrexa Viscous and Photrexa$164
- Hydrus Microstent$119
- STELLARIS$116
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR CARTRIDGE$113
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
How this compares
Too few cornea and external diseases specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 696 | $21,396 |
| MoxifloxacinMoxifloxacin Hcl | 536 | $12,111 |
| Ketorolac Tromethamine | 488 | $8,301 |
| ValacyclovirValacyclovir Hcl | 39 | $2,185 |
| Loteprednol Etabonate | 25 | $2,094 |
| Timolol Maleate | 36 | $768 |
| Doxycycline Hyclate | 17 | $525 |
| Gentamicin Sulfate | 16 | $300 |
| Latanoprost | 27 | $285 |
| ErythromycinErythromycin Base | 23 | $253 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 20 | $165 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $125 |
| Brimonidine Tartrate | 22 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $501 | $2,09425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Arkansason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.